CareDx, Inc (NASDAQ:CDNA - Get Free Report) saw unusually-high trading volume on Monday . Approximately 1,810,291 shares changed hands during mid-day trading, an increase of 130% from the previous session's volume of 785,897 shares.The stock last traded at $24.32 and had previously closed at $22.41.
Analyst Upgrades and Downgrades
CDNA has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a "neutral" rating and issued a $26.00 target price on shares of CareDx in a research report on Tuesday, January 14th. StockNews.com raised shares of CareDx from a "hold" rating to a "buy" rating in a research report on Thursday, October 17th. Wells Fargo & Company raised shares of CareDx from an "underweight" rating to an "equal weight" rating and dropped their target price for the company from $28.00 to $24.00 in a research report on Wednesday, January 15th. Finally, BTIG Research dropped their target price on shares of CareDx from $40.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, November 5th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, CareDx currently has an average rating of "Moderate Buy" and an average price target of $28.33.
Get Our Latest Research Report on CareDx
CareDx Stock Performance
The company has a market capitalization of $1.31 billion, a PE ratio of -9.07 and a beta of 1.87. The company's 50-day simple moving average is $22.69 and its 200-day simple moving average is $25.32.
Insiders Place Their Bets
In other news, Director Peter Maag sold 5,000 shares of the firm's stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the sale, the director now owns 330,024 shares in the company, valued at approximately $8,250,600. This trade represents a 1.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.90% of the stock is currently owned by insiders.
Institutional Trading of CareDx
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Quarry LP purchased a new stake in shares of CareDx during the third quarter worth about $27,000. Thompson Davis & CO. Inc. grew its holdings in shares of CareDx by 6.3% during the fourth quarter. Thompson Davis & CO. Inc. now owns 16,050 shares of the company's stock worth $344,000 after buying an additional 950 shares in the last quarter. Royce & Associates LP grew its holdings in shares of CareDx by 0.3% during the third quarter. Royce & Associates LP now owns 393,286 shares of the company's stock worth $12,280,000 after buying an additional 1,000 shares in the last quarter. Hsbc Holdings PLC grew its holdings in shares of CareDx by 6.9% during the fourth quarter. Hsbc Holdings PLC now owns 17,131 shares of the company's stock worth $365,000 after buying an additional 1,109 shares in the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of CareDx by 1.3% during the fourth quarter. Legal & General Group Plc now owns 89,751 shares of the company's stock worth $1,922,000 after buying an additional 1,118 shares in the last quarter.
About CareDx
(
Get Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
Featured Stories
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
